Pfizer's animal health unit Zoetis prices IPO at $26, above the range

By Renaissance Capital,

Shutterstock photo

Zoetis, a spin-off of Pfizer's global animal health medicines and vaccines business, raised $2.2 billion by offering 86.1 million shares at $26, above the range of $22 to $25. Zoetis plans to list on the NYSE under the symbol ZTS. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ZTS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by